secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2026-10-15T20:00:53+00:00
Accession:  0001104659-26-116227
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4.1-flash:cloud@v2

AbbVie expands board to 13, appoints Dr. John M. Carethers as Class II director
-------------------------------------------------------------------------------

- Board size increased from twelve to thirteen directors on October 14, 2026; Dr. John M. Carethers named a Class II director.
- Carethers is Vice Chancellor for Health Sciences at University of California San Diego and was previously a director of Avantor, Inc.
- Board determined Carethers is independent under NYSE section 303A.02 and AbbVie's Governance and Director Independence Guidelines.
- He was appointed to the Public Policy and Sustainability Committee of the AbbVie board.
- Compensation will follow independent-director terms disclosed in Exhibit 10.5 to AbbVie's Form 10-Q for the quarter ended March 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000110465926116227/0001104659-26-116227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000110465926116227/tm2627361d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-116227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer